Table 2.

Univariate and multivariate association of weight changes with major CV outcomes in CANVAS. Entries are Hazard Ratio [95% confidence interval]

	hHF (n = 197)	hHF or CV Death (n = 409)	MACE (n = 712)	Non-fatal MI (n = 313)
Univariate
Gainers vs Stable	1.85 [1.22–2.72]	1.84 [1.38–2.40]	1.26 [0.99–1.59]	1.25 [0.86–1.76]
Losers vs Stable	2.06 [1.40–2.95]	1.67 [1.26–2.18]	1.23 [0.97–1.54]	1.33 [0.93–1.83]
Cana vs placebo	0.60 [0.45–0.79]	0.76 [0.63–0.93]	0.91 [0.78–1.06]	0.86 [0.69–1.08]
Multivariate
Gainers vs Stable	1.43 [0.93–2.13]	1.61 [1.20–2.13]	1.17 [0.91–1.47]	1.14 [0.78–1.62]
Losers vs Stable	1.67 [1.11–2.46]	1.53 [1.14–2.03]	1.18 [0.92–1.49]	1.27 [0.88–1.78]
Cana vs placebo	0.60 [0.45–0.80]	0.78 [0.64–0.96]	0.92 [0.78–1.07]	0.85 [0.68–1.08]
Sex (male)	1.09 [0.79–1.55]	1.02 [0.82–1.29]	1.27 [1.07–1.52]	1.63 [1.24–2.17]
Age (SD)	1.72 [1.47–2.03]	1.54 [1.38–1.72]	1.26 [1.17–1.37]	1.13 [1.00–1.28]
Baseline weight (SD)	1.45 [1.25–1.68]	1.21 [1.09–1.35]	1.09 [1.01–1.19]	1.09 [0.97–1.23]
Ln[UACR (mg/g)]	1.37 [1.27–1.48]	1.37 [1.29–1.44]	1.16 [1.11–1.22]	1.01 [0.94–1.09]
Smoking	1.03 [0.66–1.56]	1.19 [0.89–1.55]	1.01 [0.82–1.24]	0.86 [0.62–1.18]
Use of diuretics	2.25 [1.63–3.13]	1.72 [1.40–2.13]	1.05 [0.90–1.23]	1.03 [0.82–1.30]
Use of statins	1.04 [0.73–1.54]	0.81 [0.64–1.02]	0.75 [0.63–0.89]	0.93 [0.71–1.24]
Use of antithrombotics	2.49 [1.59–4.12]	2.10 [1.58–2.83]	1.65 [1.35–2.01]	1.77 [1.30–2.46]
Use of insulin	1.12 [0.80–1.58]	1.17 [0.93–1.48]	1.21 [1.02–1.44]	1.26 [0.98–1.64]
Use of metformin	0.68 [0.50–0.92]	0.69 [0.56–0.85]	0.74 [0.63–0.87]	0.84 [0.66–1.09]
Use of sulphonylureas	1.18 [0.85–1.63]	1.23 [0.98–1.53]	0.93 [0.78–1.10]	0.85 [0.66–1.10]
Use of GLP-1 RA	1.60 [0.86–2.74]	1.40 [0.83–2.19]	1.07 [0.69–1.58]	0.93 [0.50–1.72]

hHF, hospitalization for heart failure; CV, cardiovascular; MACE, major adverse cardiovascular events; MI, myocardial infarction; SD, standard deviation; UACR, urinary albumin-to-creatinine ratio; GLP-1 RA, glucagon-like peptide-1 receptor agonists